Belite Bio, a clinical-stage company developing treatments for degenerative retinal diseases, announced it will participate in a virtual investor symposium hosted by Piper Sandler on July 9, 2026. The company will engage in a fireside chat to discuss its lead drug candidate, tinlarebant, which targets Stargardt disease type 1 and geographic atrophy in dry age-related macular degeneration. Belite Bio recently completed a successful Phase 3 trial and is continuing further clinical studies. The webcast will be available on Belite Bio's investor relations website and archived for 90 days.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...
The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...
MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...
A securities class action lawsuit was filed against Millrose Properties, Inc. for allegedly misleading investors by not disclosing that it would lease $200 million worth of properties purchased from Lennar at a loss. The lawsuit claims Millrose misre...
Brookfield Infrastructure Corporation has postponed its special shareholder meeting to October 29, 2026, to allow more time for votes on its proposed corporate simplification. The plan aims to merge Brookfield Infrastructure Partners LP and Brookfiel...
